Regenxbio Inc (NAS:RGNX)
$ 10 0.08 (0.81%) Market Cap: 495.45 Mil Enterprise Value: 320.09 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 65/100

Regenxbio Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 06:55PM GMT
Release Date Price: $26.82 (+1.86%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Okay. Let's go ahead and get started. Thanks, everyone, for joining. This is the fireside chat with REGENXBIO. I'm happy to have with me, Ken Mills, CEO; and Ram Palanki EVP of Commercial Strategy. Thanks for joining us again. My name is Vikram Purohit, one of the biotech analysts with Morgan Stanley Research. And before we get started, I need to read a brief disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.

With that, Ken, Ram, thanks for joining. Appreciate it.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Thanks for having us.

Questions & Answers

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Of course.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot